Other Events ·
Stockholders approve Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5,000,000 to 9,000,000 and extending plan term to January 31, 2030
FLNAFilana Therapeutics, Inc.
On June 11, 2026, stockholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5,000,000 to 9,000,000 and extending the plan term to January 31, 2030. The amendment prohibits the repricing, replacing, or cash-out of stock options or SARs without stockholder approval and reduces maximum annual compensation limits for non-employee directors and individual equity awards. Other annual meeting results included the election of directors Richard J. Barry, Pierre Gravier, and Claude Nicaise, and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026. Filana Therapeutics, Inc. is a biotechnology company that develops therapeutic treatments.